bdc-3042
bolt biotherap
['bdc-3042']
#boltbio is presenting new preclinical data for bdc-3042, a proprietary dectin-2 targeting agonistic antibody, at #aacr23 today. view our poster presentation here: 
Unleashing the power of the immune system to achieve anti-tumor immunity for the nearly 80% of patients who are unresponsive to checkpoint inhibitors.